First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

by Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T
Published 2014

A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea

by Coyle, V M, Lungulescu, D, Toganel, C, Niculescu, A, Pop, S, Ciuleanu, T, Cebotaru, C, Devane, J, Martin, M, Wilson, R H
Published 2013

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients

by Krikelis, Dimitrios, Bobos, Mattheos, Karayannopoulou, Georgia, Resiga, Liliana, Chrysafi, Sofia, Samantas, Epaminontas, Andreopoulos, Dimitrios, Vassiliou, Vassilios, Ciuleanu, Elisabeta, Fountzilas, George
Published 2013

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

by Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose
Published 2014

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study

by Negru, Serban, Papadopoulou, Eirini, Apessos, Angela, Stanculeanu, Dana Lucia, Ciuleanu, Eliade, Volovat, Constantin, Croitoru, Adina, Kakolyris, Stylianos, Aravantinos, Gerasimos, Ziras, Nikolaos, Athanasiadis, Elias, Touroutoglou, Nikolaos, Pavlidis, Nikolaos, Kalofonos, Haralabos P, Nasioulas, George
Published 2014

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast...

by Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T. W., Yang, L., Nasroulah, F., Tabernero, J.
Published 2016

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

by Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Published 2014

Report from the OECI Oncology Days 2014

by van Harten, WH, Stanta, G, Bussolati, G, Riegman, P, Hoefler, G, Becker, KF, Folprecht, G, Truini, M, Haybaeck, J, Buiga, R, Dono, M, Bagg, A, López Guerrero, JA, Zupo, S, Lemare, F, de Lorenzo, F, Goedbloed, N, Razavi, D, Lövey, J, Cadariu, PA, Rollandi, GA, Paparo, F, Pierotti, M, Ciuleanu, T, De Paoli, P, Weiner, G, Saghatchian, M, Lombardo, Claudio
Published 2014